revlimid Report issue

Biological Experimental
AACT ChEMBL Drug Central PubChem

Active Ingredient History

NOW
  • Now
Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). For multiple myeloma, it is used after at least one other treatment and generally with dexamethasone. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O
  • InChIKey: GOTYRUGSSMKFNF-UHFFFAOYSA-N
  • Mol. Mass: 259.26
  • ALogP: 0.03
  • ChEMBL Molecule:
    lenalidomide  
More Chemistry

Pharmacology

  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

pvx-410 | revlimid

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Breast Neoplasms (Phase 1)

Burkitt Lymphoma (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 2)

Smoldering Multiple Myeloma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue